A randomized phase III trial of neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy and adjuvant durvalumab in muscle-invasive bladder cancer (NIAGARA)

被引：0

作者：

Powles, T. B. ^{[1
]}

van der Heijden, M. S. ^{[2
]}

Galsky, M. D. ^{[3
]}

Al-Ahmadie, H. ^{[4
]}

Meeks, J. J. ^{[5
]}

Nishiyama, H. ^{[6
]}

Vu, T. Q. ^{[7
]}

Antonuzzo, L. ^{[8
]}

Wiechno, P. ^{[9
]}

Atduev, V. ^{[10
]}

Kann, A. G. ^{[11
]}

Kim, T-H. ^{[12
]}

Rodriguez, C. Suarez ^{[13
]}

Chang, C-H. ^{[14
,15
]}

Roghmann, F. ^{[16
]}

Ozguroglu, M. ^{[17
]}

Armstrong, J. ^{[18
]}

Ho, S. ^{[19
]}

Hois, S. ^{[19
]}

Catto, J. ^{[20
,21
]}

机构：

[1] Queen Mary Univ London, Barts Canc Inst, Genitourinary Oncol, London, England

[2] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands

[3] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA

[4] Mem Sloan Kettering Canc Ctr, Dept Pathol & Lab Med, New York, NY USA

[5] Northwestern Univ, Feinberg Sch Med, Dept Urol Biochem & Mol Genet, Chicago, IL USA

[6] Univ Tsukuba, Dept Urol, Tsukuba, Ibaraki, Japan

[7] Vietnam Natl Canc Hosp, Dept Internal Med 3, Hanoi, Vietnam

[8] Univ Careggi, Azienda Osped, SODc Oncol Med, Florence, Italy

[9] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Urooncol, Warsaw, Poland

[10] Fed Med Biol Agcy, Volga Dist Med Ctr, Nizhnii Novgorod, Russia

[11] Hosp Alemao Oswaldo Cruz, Oncol Clin, Sao Paulo, Brazil

[12] Kyungpook Natl Univ, Sch Med, Dept Urol, Daegu, South Korea

[13] Hosp Univ Vall Hebron, Vall Hebron Inst Oncol VHIO, Med Oncol, Vall Hebron Barcelona Hosp Campus, Barcelona, Spain

[14] China Med Univ & Hosp, Dept Urol, Taichung, Taiwan

[15] China Med Univ & Hosp, Sch Med, Taichung, Taiwan

[16] Ruhr Univ Bochum, Marien Hosp, Univ Hosp, Dept Urol, Herne, Germany

[17] Istanbul Univ Cerrahpasa, Cerrahpasa Med Sch, Dept Internal Med, Istanbul, Turkey

[18] AstraZeneca, Stat, Cambridge, England

[19] AstraZeneca, Oncol, Gaithersburg, MD USA

[20] Univ Sheffield, Sch Med & Populat Hlth, Div Clin Med, Sheffield, S Yorkshire, England

[21] Sheffield Teaching Hosp NHS Fdn Trust, Sheffield, S Yorkshire, England

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.2327

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA5

引用

页码：1271 / 1271

页数：1

共 50 条

[1] A phase III, randomized, open-label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine plus cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (NIAGARA).
Powles, Thomas
Meeks, Joshua J.
Galsky, Matt D.
Van der Heijden, Michiel Simon
Nishiyama, Hiroyuki
Al-Ahmadie, Hikmat A.
Goluboff, Erik T.
Hois, Stephan
Donegan, Sarah E.
Williams, Vanessa
Xiao Feng
Catto, James W. F.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[2] A phase III, randomized, open label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine plus cisplatin (G plus C) for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (MIBC) (NIAGARA).
Powles, Thomas
Meeks, Joshua J.
Galsky, Matt D.
Van der Heijden, Michiel Simon
Nishiyama, Hiroyuki
Al-Ahmadie, Hikmat
Gupta, Ashok Kumar
Ye, Jiabu
Donegan, Sarah E.
Ghiorghiu, Dana C.
Ferro, Salvatore
Catto, James W. F.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[3] Neoadjuvant chemotherapy with gemcitabine plus carboplatin followed by immediate radical cystectomy for muscle-invasive bladder cancer
Ohyama, Chikara
Hatakeyama, Shingo
Yoneyama, Takahiro
Koie, Takuya
INTERNATIONAL JOURNAL OF UROLOGY, 2014, 21 (01) : 3 - 4
[4] AEGEAN: a phase 3 trial of neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC
Schumann, C.
Heymach, J. V.
Harpole, D.
Mitsudomi, T.
Taube, J. M.
Galffy, G.
Hochmair, M.
Winder, T.
Zukov, R.
Garbaos, G.
Gao, S.
Kuroda, H.
You, J.
Lee, K. -Y.
Antonuzzo, L.
Aperghis, M.
Doherty, G. J.
Mann, H.
Fouad, T. M.
Reck, M.
Weissinger, F.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 8 - 9
[5] PHASE 2 TRIAL OF NEOADJUVANT GEMCITABINE AND CARBOPLATIN FOR MUSCLE-INVASIVE BLADDER CANCER FOLLOWED BY RADICAL CYSTECTOMY
Koie, Takuya
Okamoto, Teppei
Imanishi, Kengo
Sugiyama, Naoki
Kudoh, Shigemasa
Mori, Kazuyuki
Tachiwada, Tokushi
Yoneyama, Takahiro
Hashimoto, Yasuhiro
Kamimura, Noritaka
Ohyama, Chikara
Suzuki, Yuichiro
JOURNAL OF UROLOGY, 2010, 183 (04): : E657 - E657
[6] A Phase 3, Randomized, Open-Label, Multicenter, Global Study of Efficacy and Safety of Durvalumab in Combination with Gemcitabine plus CiSPLATiN (G plus C) for Neoadjuvant Treatment Followed By Durvalumab Alone for Adjuvant Treatment in Muscle-Invasive Bladder Cancer (MiBC) (NiAGARA)
Kuebler, Hubert Rudolf
Powles, Thomas
Meeks, Joshua J.
Galsky, Matthew
van der Heijdens, Michel S.
Nishiyama, Hiroyuki
Al-Ahmadie, Hikmat
Gupta, Ashok
Ye, Jiabu
Donegan, Sarah
Ghiorghiu, Dana
Ferro, Salvatore
Catto, James
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 82 - 82
[7] Neoadjuvant Therapy Schemes combined with adjuvant Therapy for Patients with muscle invasive Bladder Cancer before or after radical Cystectomy A randomized, open, multicenter, global Phase-III Study to Determine the Efficacy and Safety of Durvalumab in combination with Gemcitabine plus Cisplatin (G plus C) for neoadjuvant Treatment, followed by Durvalumab alone for adjuvant Treatment in Patients with muscle invasive Bladder Cancer ( NIAGARA) - AUO AB 74/20
Rexer, Heidrun
Kuebler, Hubert
Retz, Margitta
AKTUELLE UROLOGIE, 2021, 52 (03) : 220 - 221
[8] Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer
Milowsky, Matthew I.
Stadler, Walter M.
Bajorin, Dean F.
BJU INTERNATIONAL, 2008, 102 (09) : 1339 - 1344
[9] Surgical Outcomes with Neoadjuvant Durvalumab plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC (AEGEAN)
Mitsudomi, T.
Heymach, J. V.
Reck, M.
Taube, J. M.
Gao, S.
Horio, Y.
You, J.
Li, G.
Van Luong, D.
Saeteng, S.
Tanaka, F.
Kulesza, G.
Watzka, S. B.
Urban, L.
Szalai, Z.
Akamatsu, H.
Kang, J. -H.
Orlandi, F. J.
Mukhametshina, G. Z.
Pircher, A.
Teixeira, C. H. A.
Aperghis, M.
Doherty, G. J.
Doake, R.
Fouad, T. M.
Harpole, D.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S71 - S72
[10] Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial
Cognetti, F.
Ruggeri, E. M.
Felici, A.
Gallucci, M.
Muto, G.
Pollera, C. F.
Massidda, B.
Rubagotti, A.
Giannarelli, D.
Boccardo, F.
ANNALS OF ONCOLOGY, 2012, 23 (03) : 695 - 700

← 1 2 3 4 5 →